SLC2A1 and prostate cancer: Glut1 expression in prostate cancer is highly variable with some reports showing a low to very low frequency of Glut1 immunostaining [16, 17] and a high to very high frequency in others [18, 19], with no relationship with Gleason score, T stage or PSA.